Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:AXNX

Axonics (AXNX) Stock Price, News & Analysis

Axonics logo

About Axonics Stock (NASDAQ:AXNX)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$70.98
$70.98
50-Day Range
$69.66
$70.98
52-Week Range
$66.32
$71.05
Volume
N/A
Average Volume
432,118 shs
Market Capitalization
$3.63 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

Remove Ads
Receive AXNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axonics and its competitors with MarketBeat's FREE daily newsletter.

AXNX Stock News Headlines

Axonics Modulation Technologies Merges and Delists from Nasdaq
Collect $7k per month from Tesla’s SECRET dividend
Tesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69% dividend from Tesla… Which could put up to $7,013 in your pocket every month…
Boston Scientific Closes Acquisition of Axonics, Inc.
See More Headlines

AXNX Stock Analysis - Frequently Asked Questions

Axonics, Inc. (NASDAQ:AXNX) released its earnings results on Thursday, November, 7th. The company reported $0.16 earnings per share for the quarter, topping analysts' consensus estimates of $0.11 by $0.05. Axonics's quarterly revenue was up 24.8% compared to the same quarter last year.

Axonics (AXNX) raised $100 million in an initial public offering (IPO) on Wednesday, October 31st 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch and Morgan Stanley served as the underwriters for the IPO and Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Axonics investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), NVIDIA (NVDA), TotalEnergies (TTE) and The RMR Group (RMR).

Company Calendar

Last Earnings
11/07/2024
Today
4/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:AXNX
Employees
610
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
322.64
P/E Growth
N/A
Net Income
$-6,090,000.00
Pretax Margin
-0.70%

Debt

Sales & Book Value

Annual Sales
$366.38 million
Cash Flow
$0.13 per share
Price / Cash Flow
561.96
Book Value
$12.59 per share
Price / Book
5.64

Miscellaneous

Free Float
50,163,000
Market Cap
$3.63 billion
Optionable
Optionable
Beta
0.82
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:AXNX) was last updated on 4/8/2025 by MarketBeat.com Staff
From Our Partners